Hyperbranched Cationic Glycogen Derivative-Mediated IκBα Gene Silencing Regulates the Uveoscleral Outflow Pathway in Rats

Table 2

Grouping and treatment of animals.

Group	Treatment^a
PBS group	PBS
DMAPA-Glyp group	DMAPA-Glyp solution containing 25 μg of DMAPA-Glyp
DMAPA-Glyp+NC group	DMAPA-Glyp and NC-siRNA complex containing 25 μg of DMAPA-Glyp and 5 μg of NC-siRNA
siRNA group	IκBα-siRNA solution containing 5 μg of IκBα-siRNA
Lipo+siRNA group	Lipofectamine™ 2000 and IκBα-siRNA complex containing 1.5 μl of Lipofectamine™ 2000 and 5 μg of IκBα-siRNA
DMAPA-Glyp+siRNA group	DMAPA-Glyp and IκBα-siRNA complex containing 25 μg of DMAPA-Glyp and 5 μg of IκBα-siRNA

^aIntracameral injection with a volume of 10 μl per eye. Abbreviations: PBS—phosphate-buffered saline; DMAPA-Glyp—3-(dimethylamino)-1-propylamine-conjugated glycogen; NC-siRNA—nonspecific control siRNA; Lipo—Lipofectamine™ 2000.